1. Phase I and pharmacokinetic study of imatinib mesylate (Gleevec) and gemcitabine in patients with refractory solid tumors;Ali;Clin. Cancer Res.,2007
2. Single-Agent pembrolizumab for patients with malignant pleural mesothelioma (MPM);Alley;Paper Presented At: International Association for the Study of Lung Cancer, 16th World Conference on Lung Cancer,2015
3. Human and mouse mesotheliomas exhibit elevated AKT/PKB activity, which can be targeted pharmacologically to inhibit tumor cell growth;Altomare;Oncogene,2005
4. Losses of both products of the Cdkn2a/Arf locus contribute to asbestos-induced mesothelioma development and cooperate to accelerate tumorigenesis;Altomare;PLoS One,2011
5. Nintedanib (BIBF 1120) in Mesothelioma. ClinicalTrials.gov Identifier: NCT01907100. https://clinicaltrials.gov/ct2/show/NCT01907100.